Immunitrack congratulates Michael Platten and Wolfgang Wick from the German Cancer Research Center (DKFZ) and other collaborators on very promising Phase I trial results on IDH-vac, a peptide vaccine for immunotherapy in newly diagnosed IDH1+ glioma.
IDH-vac includes the most common IDH1 mutation, IDH1(R132H). IDH1(R132H) harbours a shared clonal neo-epitope that is presented on major histocompatibility complex (MHC) class II molecules, and the vaccine is designed to induce specific therapeutic T helper cell responses against IDH1+ tumours.
The Phase I trial found that IDH-vac induces an immune response in 93.3% of patients across multiple MHC alleles. Patients with immune responses exhibited a two-year progression-free rate of 0.82. The trial also revealed strong intra-tumoural inflammatory reactions resulting from vaccine-induced peripheral T cell responses that were dominated by a single IDH(R132H)-reactive T cell receptor.
NeoScreen® MHC/Peptide Binding Assays
Immunitrack was responsible for the MHC/IDH and MHC/IDH (R132H) binding assessments in this study which included analysis of more than 10 MHC class II molecules: DRB1*01:01, DRB1*03:01, DRB1*04:01, DRB1*11:01, DRB1*13:01, DRB1*1501, DRB3*01:01, DRB3*0202, DRB4:0101, DRB5*01:01, DPA1*01:03/DPB1*04:01.
The results were recently published in Nature journal ▸